Arbutus Biopharma (ABUS) Competitors

Arbutus Biopharma logo
$4.09 -0.02 (-0.58%)
Closing price 03:59 PM Eastern
Extended Trading
$4.11 +0.03 (+0.69%)
As of 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABUS vs. IRON, IDYA, BEAM, XNCR, and ZLAB

Should you buy Arbutus Biopharma stock or one of its competitors? Arbutus Biopharma's main competitors and comparable companies include Disc Medicine (IRON), IDEAYA Biosciences (IDYA), Beam Therapeutics (BEAM), Xencor (XNCR), and Zai Lab (ZLAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arbutus Biopharma compare to Disc Medicine?

Arbutus Biopharma (NASDAQ:ABUS) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Arbutus Biopharma has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$14.08M44.48-$33.50M$1.133.62
Disc MedicineN/AN/A-$212.18M-$6.34N/A

In the previous week, Disc Medicine had 6 more articles in the media than Arbutus Biopharma. MarketBeat recorded 7 mentions for Disc Medicine and 1 mentions for Arbutus Biopharma. Disc Medicine's average media sentiment score of 0.70 beat Arbutus Biopharma's score of 0.00 indicating that Disc Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arbutus Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Disc Medicine
3 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arbutus Biopharma has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Disc Medicine has a consensus price target of $125.27, suggesting a potential upside of 64.59%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Disc Medicine is more favorable than Arbutus Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79

Arbutus Biopharma has a net margin of 121.17% compared to Disc Medicine's net margin of 0.00%. Arbutus Biopharma's return on equity of 129.12% beat Disc Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Arbutus Biopharma121.17% 129.12% 89.26%
Disc Medicine N/A -36.33%-32.50%

Summary

Arbutus Biopharma beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to IDEAYA Biosciences?

Arbutus Biopharma (NASDAQ:ABUS) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Arbutus Biopharma has a net margin of 121.17% compared to IDEAYA Biosciences' net margin of -1,157.18%. Arbutus Biopharma's return on equity of 129.12% beat IDEAYA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arbutus Biopharma121.17% 129.12% 89.26%
IDEAYA Biosciences -1,157.18%-39.78%-36.25%

Arbutus Biopharma has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$14.08M44.48-$33.50M$1.133.62
IDEAYA Biosciences$218.71M11.57-$113.70M-$4.49N/A

IDEAYA Biosciences has a consensus price target of $49.55, suggesting a potential upside of 89.29%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Arbutus Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
IDEAYA Biosciences
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, IDEAYA Biosciences had 16 more articles in the media than Arbutus Biopharma. MarketBeat recorded 17 mentions for IDEAYA Biosciences and 1 mentions for Arbutus Biopharma. IDEAYA Biosciences' average media sentiment score of 0.12 beat Arbutus Biopharma's score of 0.00 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arbutus Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
IDEAYA Biosciences
1 Very Positive mention(s)
5 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Arbutus Biopharma has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Arbutus Biopharma beats IDEAYA Biosciences on 8 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to Beam Therapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Beam Therapeutics has a consensus price target of $47.64, suggesting a potential upside of 127.32%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Arbutus Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75

Arbutus Biopharma has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$14.08M44.48-$33.50M$1.133.62
Beam Therapeutics$139.74M15.52-$79.99M-$1.04N/A

In the previous week, Beam Therapeutics had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 5 mentions for Beam Therapeutics and 1 mentions for Arbutus Biopharma. Beam Therapeutics' average media sentiment score of 0.34 beat Arbutus Biopharma's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arbutus Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Beam Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arbutus Biopharma has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

Arbutus Biopharma has a net margin of 121.17% compared to Beam Therapeutics' net margin of -73.04%. Arbutus Biopharma's return on equity of 129.12% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arbutus Biopharma121.17% 129.12% 89.26%
Beam Therapeutics -73.04%-32.76%-25.80%

Summary

Beam Therapeutics beats Arbutus Biopharma on 9 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Xencor?

Arbutus Biopharma (NASDAQ:ABUS) and Xencor (NASDAQ:XNCR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Xencor has a consensus target price of $44.00, indicating a potential upside of 29.37%. Given Xencor's stronger consensus rating and higher possible upside, analysts clearly believe Xencor is more favorable than Arbutus Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64

Arbutus Biopharma has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$14.08M44.48-$33.50M$1.133.62
Xencor$125.58M20.32-$91.92M-$1.59N/A

43.8% of Arbutus Biopharma shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arbutus Biopharma has a net margin of 121.17% compared to Xencor's net margin of -58.79%. Arbutus Biopharma's return on equity of 129.12% beat Xencor's return on equity.

Company Net Margins Return on Equity Return on Assets
Arbutus Biopharma121.17% 129.12% 89.26%
Xencor -58.79%-21.28%-15.17%

Arbutus Biopharma has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Xencor has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

In the previous week, Xencor had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 5 mentions for Xencor and 1 mentions for Arbutus Biopharma. Xencor's average media sentiment score of 0.83 beat Arbutus Biopharma's score of 0.00 indicating that Xencor is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arbutus Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Xencor
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Arbutus Biopharma beats Xencor on 9 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Zai Lab has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Arbutus Biopharma has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$460.16M5.96-$175.54M-$1.79N/A
Arbutus Biopharma$14.08M44.48-$33.50M$1.133.62

Arbutus Biopharma has a net margin of 121.17% compared to Zai Lab's net margin of -44.91%. Arbutus Biopharma's return on equity of 129.12% beat Zai Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-44.91% -31.15% -18.17%
Arbutus Biopharma 121.17%129.12%89.26%

Zai Lab currently has a consensus price target of $38.50, indicating a potential upside of 75.64%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts plainly believe Zai Lab is more favorable than Arbutus Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Arbutus Biopharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Zai Lab had 13 more articles in the media than Arbutus Biopharma. MarketBeat recorded 14 mentions for Zai Lab and 1 mentions for Arbutus Biopharma. Zai Lab's average media sentiment score of 0.67 beat Arbutus Biopharma's score of 0.00 indicating that Zai Lab is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zai Lab
5 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Arbutus Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Arbutus Biopharma beats Zai Lab on 9 of the 16 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABUS vs. The Competition

MetricArbutus BiopharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$630.03M$3.98B$7.59B$11.70B
Dividend YieldN/A3.64%2.48%4.65%
P/E Ratio3.6425.7631.9526.73
Price / Sales44.4815.788.415.55
Price / CashN/A22.6520.7221.66
Price / Book7.304.294.423.65
Net Income-$33.50M-$23.99M$3.51B$394.00M
7 Day Performance1.39%-7.12%-6.16%-6.39%
1 Month Performance-3.40%-9.02%-7.05%-8.77%
1 Year Performance-4.31%-6.67%-2.52%-8.48%

Arbutus Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABUS
Arbutus Biopharma
0.8176 of 5 stars
$4.09
-0.6%
N/A-7.6%$630.03M$14.08M3.6419
IRON
Disc Medicine
3.368 of 5 stars
$81.26
+3.0%
$124.18
+52.8%
-13.1%$3.20BN/AN/A165
IDYA
IDEAYA Biosciences
3.3609 of 5 stars
$32.03
+2.5%
$49.55
+54.7%
-21.4%$3.13B$218.71MN/A145
BEAM
Beam Therapeutics
2.4103 of 5 stars
$27.02
+2.3%
$47.36
+75.3%
-4.2%$2.88B$139.74MN/A540
XNCR
Xencor
2.8119 of 5 stars
$38.59
+7.9%
$42.22
+9.4%
+114.7%$2.60B$125.58MN/A260

Related Companies and Tools


This page (NASDAQ:ABUS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners